Sandy Lin


Sandy Lin
Sandy Lin is a partner in the Corporate Department of the Firm’s Hong Kong office. Sandy’s practice is focused on complex cross-border transactions in the Asia-Pacific region, including mergers and acquisitions, cross-border joint ventures, emerging companies, venture capital financing, and energy project development. Having spent a significant part of her career in China, she is in particular experienced in China-related cross-border transactions. She regularly represents international and regional private equity sponsors, state-owned companies, sovereign wealth funds, private companies and other investors in various industries, including energy, infrastructure, TMT, biotechnology, healthcare, pharmaceutical, medical devices, automobile, manufacturing and chemicals.

Sandy was named a “Rising Star Partner” for Private Equity practice in the IFLR1000 Asia-Pacific 2023 and a “Next Generation Partner” for Private Equity and Corporate and M&A practice in the Legal 500 Asia-Pacific 2024. Clients lauded Sandy as ‘a great mind who can provide to-the-point and useful solutions to complicated situations’, who ‘stands out for her depth of international experience, effectiveness, and her talent in assembling and mobilising a brilliant and effective team.’

Sandy is a native Mandarin and English speaker and is qualified as an attorney in Washington D.C.

Sandy’s recent representations include*:

  • Baring Private Equity Asia in the sale of China headquartered HCP Packaging, a global leader in the design, development and manufacture of cosmetics packaging, to The Carlyle Group
  • TPG Capital Asia, TPG Growth and Ontario Teachers’ Pension Plan in connection with the multi-jurisdictional restructuring of Dream Cruises Holding Limited, a premium brand, Asian-sourced passenger cruise line, and its parent company Genting Hong Kong Limited, involving $2.6 billion in debt and $700 million in new money
  • TPG in multiple matters, including (1) as part of a consortium led by Singapore Life Pte. Ltd. in the consortium’s $2 billion acquisition of Aviva Singapore, a licensed provider of health and general insurance, a trust platform and financial advisory services, from AVIVA International Insurance Limited and (2) the acquisition by TPG Capital AsiaTPG Growth and Ontario Teachers’ Pension Plan in the acquisition of up to 35% of Dream Cruises Holding Limited, a premium brand, Asian-sourced passenger cruise line with an enterprise value based on the transaction of $3.3 billion, from Genting Hong Kong Limited, the largest cruise operator in the Asia Pacific region. The transaction was awarded M&A Deal of the Year at the Asian Legal Business Hong Kong Law Awards 2020
  • MBK Partners in multiple matters, including (1) its acquisition of a 20.86% stake in CAR Inc. (HKSE: 0699), China’s largest car rental service provider, (2) the $2.2 billion (including debt) take-private of CAR Inc. by way of a voluntary general offer (the transaction was the second-largest privatization in China during 2020 and was named 2021 Private Equity Deal of the Year at Mergermarket China M&A Awards), (3) the acquisition of a controlling stake in Wendu Education Group, the largest provider of National Graduate Entrance Examination tutoring services in China and (4)the acquisition of a controlling stake in Siyanli, a leading high-end beauty spa and medical beauty service provider in China
  • Alibaba Group Holding Limited in its secondary purchase of shares in Bilibili, Inc., a leading online entertainment company in China
  • Anchor Equity Partners in the Series A funding round for Cue Holdings Limited, a provider of integrated digital marketing solutions in China backed by KKR
  • A leading Asian PE firm in its minority investment in a developer of a security software platform that provides cyber risk solutions
  • A Chinese SOE in connection with an acquisition of an independent wind power producer in Brazil, with a deal value of approximately $700 million
  • A Chinese SOE in connection with a minority investment in a Brazilian private port
  • A Chinese consortium in connection with an acquisition of a U.S. based biotechnology company, with a deal value of approximately $300 million
  • A Chinese biotechnology company in connection with the acquisition of an equity stake in a U.S. biotechnology company and the entry into a licensing arrangement in connection with key technologies

*Includes matters handled prior to joining Weil